This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
Kerry Hotel Pudong
April 23–24, 2025 | Shanghai, ChinaApril 29–30, 2025 | Virtual

Jiansheng Tang
CEO at Novastage Pharmaceuticals, Ltd.
Presenter

Profile

【Business Introduction】Novastage was founded on October 23, 2019, in Shenzhen City. Novastage is mainly engaged in the R&D and commercialization of transdermal patch drug products, aiming at developing innovative transdermal patches with independent intellectual property rights, international leadership and huge market potential. Novastage's transdermal technology, especially in the R&D and production of solvent patch technology is the first in China, and also leading in the world. 【Technology Advantages】Novastage was led by a team of transdermal patch experts. The founder Dr. Jiansheng Tang is one of the world's most influential leader in transdermal patch area. He worked in 3 big US pharmaceutical companies (Mylan, Teva, Aveva) for 18 years, as the R&D head , leading the development and marketing of many transdermal patches and oral films . 【Production Facilities】We have established a R&D center of 1700 m2 for three types of transdermal patch processes - solvent adhesive, hydrogel and hot melt adhesive and a pilot production plant of 1200 m2 in line with the requirements of China and US GMP. We are in the mid of completing a 10000 m2 commercial manufacture plant.